Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | CFD | P00746 | 1/20 | 0.50 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.45 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.45 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.45 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.45 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | THPO | P40225 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.45 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.45 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.45 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10617878 | 0.85 | KMO (0.49) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL406777 | 0.85 | F2 (0.44) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL30078006 | 0.85 | MAOA (0.45) | KMOF2CFDLMNACYP1A2 | |
| SCHEMBL1203107 | 0.85 | KMO (0.49) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL23411328 | 0.81 | MAOA (0.41) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL29891664 | 0.81 | MAOA (0.41) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL10619036 | 0.81 | KMO (0.45) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL11878074 | 0.80 | F2 (0.40) | KMOF2CFDGRIN2DGRIN3B | |
| SCHEMBL7410133 | 0.80 | CA12 (0.55) | KMOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL62706 | 0.77 | LMNA (0.58) | F2CFDGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2573079-A2 | Benzimidazole quinolinones and uses thereof | Novartis Vaccines and Diagnostics, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825132-B2 | Inhibition of FGFR3 and treatment of multiple myeloma | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | BARSANTI PAUL A | 2009-11-12 | — | — | US | disclosed |
| EP-1539754-A4 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2009-02-25 | — | — | EP | disclosed |
| US-7470709-B2 | Benzimidazole quinolinones and uses thereof | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | disclosed |
| EP-1692085-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | Chiron Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | CHIRON CORPORATION | 2005-11-24 | — | — | US | disclosed |
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHIRON CORPORATION | 2005-11-17 | — | — | US | disclosed |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2005-09-15 | — | — | US | disclosed |
| EP-1539754-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | Chiron Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2005047244-A2 | INHIBITION OF FGFR3 AND TREATMENT OF MULTIPLE MYELOMA | CHIRON CORPORATION (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | CHIRON CORPORATION | 2004-05-13 | — | — | US | disclosed |
| WO-2004018419-A2 | BENZIMIDAZOLE QUINOLINONES AND USES THEREOF | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
| WO-1992000978-A1 | IMIDAZOPYRIDINE PAF ANTAGONISTS | PFIZER LIMITED (GB) | 1992-01-23 | — | — | WO | disclosed |
| US-4904667-A | 1H-1,2,4-thiadiazolo(3,4-b)quinazolin-5-one-2,2-dioxides, and a method for increasing the cardiac output of a mammal with them | ORTHO PHARMACEUTICAL CORPORATION (US) | 1990-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256157-A1 | Combination therapy with CHK1 inhibitors | CHEK1, CHEK2, RAD1 | KMO 2868/4885F2 4513/4885CFD 4786/4885 |
| US-20050261307-A1 | Inhibition of FGFR3 and treatment of multiple myeloma | FGFR3, FGFR1, FGFR2 | KMO 3476/4885F2 894/4885CFD 1755/4885 |
| US-20090281100-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | KMO 809/4885F2 1650/4885CFD 4699/4885 |
| US-20050203101-A1 | Benzimidazole quinolinones and uses thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, PBRM1 | KMO 1829/4885F2 4385/4885CFD 4857/4885 |
| US-20040092535-A1 | Benzimidazole quinolinones and uses thereof | GAA, ALPI, IL4I1 | KMO 812/4885F2 1740/4885CFD 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.